Events Archives - Page 13 of 128

2 minute read

Landos Biopharma To Present New Data On Immunometabolism At The 19th Annual Congress Of The European Crohn’s And Colitis Organisation

January 8, 9:26 AM

Landos Biopharma, Inc. (NASDAQ:LABP) ("Landos" or the "Company"), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced that six abstracts were

LABP

4 minute read

Vera Therapeutics To Host In-Person R&D Day In New York To Present Week 72 Data From Phase 2b ORIGIN Clinical Trial Of Atacicept In IgAN On January 25, 2024

By Benzinga Newsdesk

January 8, 9:16 AM

Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced it will host an

VERA

5 minute read

Vertex Provides Pipeline And Business Updates In Advance Of 42nd Annual J.P. Morgan Healthcare Conference On Monday, January 8, 2024 At 11:15 a.m. ET/8:15 a.m. PT

By Benzinga Newsdesk

January 7, 4:06 PM

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced multiple program updates ahead of upcoming investor meetings in January, including the company's scheduled webcast from the 42nd Annual J.P. Morgan

VRTX

1 minute read

SCYNEXIS To Present Preclinical Data On Second Generation Fungerp SCY-247 At The 11th Advances Against Aspergillosis And Mucormycosis Conference, January 25 – 27, in Milan, Italy

By Benzinga Newsdesk

January 5, 9:36 AM

SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical efficacy

SCYX

2 minute read

Insmed Provides Business Update At 42nd Annual J.P. Morgan Healthcare Conference; Sees 2024 Global ARIKAYCE Revenues $340M-$360M; Delivers FY23 Revenues Exceeding The Upper End Of Guidance Range With Unaudited Global Net Product Sales Of ~$305.2M

By Benzinga Newsdesk

January 5, 9:06 AM

—ARIKAYCE® (amikacin liposome inhalation suspension) Delivers Full-Year 2023 Revenues Exceeding the Upper End of Guidance Range with Unaudited Global Net Product Sales of Approximately $305.2 Million——2024 Global

INSM

4 minute read

Events
News

AMD Reshapes Automotive Industry With Advanced AI Engines And Elevated In-Vehicle Experiences At CES 2024

By Benzinga Newsdesk

January 4, 10:19 AM

— New Versal AI Edge XA adaptive SoCs and Ryzen Embedded V2000A Series processors underscore AMD leadership for powering next-generation automotive systems —— Participating auto ecosystem partners at CES include:

AMD

3 minute read

NRx Pharmaceuticals To Present Keynote Address On Ketamine Efficacy And Risks At Upcoming Sachs Neuroscience Innovation Forum In San Francisco

By Benzinga Newsdesk

January 2, 9:45 AM

The benefits of ketamine are clear, but so are the risksKetamine has now demonstrated clear superiority to placebo and non-inferiority to electroshock therapy in randomized trials encompassing more than 1,000 patientsNRx

NRXP

1 minute read

Events
News

Longboard Pharmaceuticals Announced Monday It Would Host Call To Discuss Topline Data From PACIFIC Study, a Phase 1b/2a Clinical Trial For Bexicaserin In Participants With Developmental And Epileptic Encephalopathies Tuesday At 8:30 AM ET

By Charles Gross

January 2, 6:59 AM

Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it will host a conference

LBPH

1 minute read

Cytokinetics To Host Investor Call On December 27 To Discuss The Topline Results From SEQUOIA-HCM, The Pivotal Phase 3 Clinical Trial Of Aficamten In Patients With Obstructive Hypertrophic Cardiomyopathy

By Benzinga Newsdesk

December 26, 5:01 PM

Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that members of its senior management will host an investor call at 8:30 AM Eastern Time on Wednesday, December 27, 2023 to discuss the topline results from

CYTK